| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 23 | 2026 | 354 | 4.640 |
Why?
|
| Carcinoma, Pancreatic Ductal | 17 | 2026 | 128 | 3.610 |
Why?
|
| Epithelial-Mesenchymal Transition | 8 | 2025 | 84 | 1.650 |
Why?
|
| Cell Plasticity | 7 | 2025 | 24 | 1.540 |
Why?
|
| Cell Lineage | 2 | 2025 | 282 | 0.960 |
Why?
|
| Neoplasms | 4 | 2024 | 1378 | 0.940 |
Why?
|
| Acinar Cells | 4 | 2024 | 8 | 0.910 |
Why?
|
| Tumor Escape | 1 | 2024 | 16 | 0.840 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 28 | 0.830 |
Why?
|
| Pancreatic Ducts | 4 | 2021 | 31 | 0.830 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2024 | 205 | 0.810 |
Why?
|
| Immune Evasion | 1 | 2024 | 71 | 0.800 |
Why?
|
| Cell Line, Tumor | 18 | 2026 | 1572 | 0.700 |
Why?
|
| Stromal Cells | 2 | 2026 | 78 | 0.700 |
Why?
|
| Mice | 28 | 2026 | 11184 | 0.680 |
Why?
|
| Pancreas, Exocrine | 1 | 2021 | 12 | 0.680 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2021 | 9 | 0.670 |
Why?
|
| Pluripotent Stem Cells | 1 | 2021 | 72 | 0.650 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 119 | 0.630 |
Why?
|
| Animals | 32 | 2026 | 21492 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2025 | 588 | 0.570 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2016 | 1 | 0.490 |
Why?
|
| Neoplasm Metastasis | 6 | 2025 | 223 | 0.480 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 62 | 0.480 |
Why?
|
| Carcinogenesis | 4 | 2024 | 135 | 0.480 |
Why?
|
| Chemokines | 1 | 2016 | 99 | 0.470 |
Why?
|
| Cellular Senescence | 3 | 2026 | 121 | 0.460 |
Why?
|
| Metaplasia | 3 | 2024 | 19 | 0.460 |
Why?
|
| Tumor Microenvironment | 6 | 2026 | 183 | 0.400 |
Why?
|
| Immunotherapy | 5 | 2026 | 274 | 0.370 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 65 | 0.350 |
Why?
|
| Humans | 32 | 2026 | 65843 | 0.350 |
Why?
|
| Organoids | 2 | 2021 | 44 | 0.340 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 645 | 0.330 |
Why?
|
| Mice, Knockout | 6 | 2024 | 2168 | 0.330 |
Why?
|
| Prostatic Neoplasms | 2 | 2026 | 504 | 0.330 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 2329 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 10 | 2026 | 3506 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2026 | 58 | 0.320 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 367 | 0.320 |
Why?
|
| Signal Transduction | 9 | 2025 | 3170 | 0.310 |
Why?
|
| Pancreas | 5 | 2024 | 153 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2025 | 314 | 0.260 |
Why?
|
| Cell Proliferation | 7 | 2025 | 1044 | 0.260 |
Why?
|
| Mitochondria | 3 | 2025 | 416 | 0.250 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 277 | 0.240 |
Why?
|
| Epithelial Cells | 3 | 2025 | 414 | 0.240 |
Why?
|
| Cachexia | 1 | 2025 | 13 | 0.230 |
Why?
|
| Thiolester Hydrolases | 1 | 2025 | 10 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2026 | 679 | 0.230 |
Why?
|
| Antigens, Neoplasm | 1 | 2026 | 134 | 0.230 |
Why?
|
| Immunologic Surveillance | 1 | 2025 | 22 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 46 | 0.220 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 309 | 0.220 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2025 | 169 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 113 | 0.220 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 4 | 0.210 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2024 | 17 | 0.210 |
Why?
|
| Tumor Hypoxia | 1 | 2024 | 1 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2024 | 52 | 0.210 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 113 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2025 | 234 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 170 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 173 | 0.200 |
Why?
|
| Immune Tolerance | 1 | 2024 | 187 | 0.200 |
Why?
|
| Hypoalbuminemia | 1 | 2023 | 7 | 0.200 |
Why?
|
| Thermogenesis | 1 | 2024 | 128 | 0.200 |
Why?
|
| Adipose Tissue, Brown | 1 | 2024 | 127 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2024 | 135 | 0.190 |
Why?
|
| Steroid Hydroxylases | 1 | 2023 | 9 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 351 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 235 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 2025 | 926 | 0.180 |
Why?
|
| Stress, Physiological | 1 | 2024 | 210 | 0.180 |
Why?
|
| Pancreatitis | 2 | 2024 | 96 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2023 | 19 | 0.180 |
Why?
|
| Cytokines | 1 | 2026 | 965 | 0.180 |
Why?
|
| Genes, myc | 1 | 2021 | 18 | 0.180 |
Why?
|
| Calcium | 1 | 2025 | 587 | 0.170 |
Why?
|
| Gene Deletion | 3 | 2019 | 312 | 0.170 |
Why?
|
| Protein Isoforms | 2 | 2019 | 201 | 0.170 |
Why?
|
| RNA, Messenger | 2 | 2026 | 1583 | 0.170 |
Why?
|
| Fibroblasts | 3 | 2022 | 423 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 75 | 0.170 |
Why?
|
| Mice, Inbred Strains | 1 | 2021 | 185 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 408 | 0.160 |
Why?
|
| Histones | 1 | 2024 | 497 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 102 | 0.160 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1391 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2024 | 829 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 94 | 0.160 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 1 | 0.160 |
Why?
|
| Calcium Signaling | 1 | 2021 | 168 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 20 | 0.150 |
Why?
|
| Apoptosis | 3 | 2019 | 1099 | 0.150 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2019 | 6 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 70 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 141 | 0.140 |
Why?
|
| Carcinoma | 1 | 2019 | 130 | 0.140 |
Why?
|
| Regulon | 1 | 2018 | 6 | 0.140 |
Why?
|
| Stem Cells | 2 | 2018 | 278 | 0.140 |
Why?
|
| Catenins | 1 | 2018 | 14 | 0.140 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 13 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2024 | 553 | 0.140 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2017 | 7 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 87 | 0.130 |
Why?
|
| Keratin-15 | 1 | 2017 | 2 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 466 | 0.130 |
Why?
|
| Interleukin-18 | 1 | 2017 | 75 | 0.130 |
Why?
|
| Interleukins | 1 | 2017 | 89 | 0.130 |
Why?
|
| Esophagus | 1 | 2017 | 47 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 712 | 0.120 |
Why?
|
| DNA Damage | 1 | 2019 | 298 | 0.120 |
Why?
|
| Smoothened Receptor | 1 | 2016 | 27 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 210 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 60 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 254 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1226 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 4 | 0.120 |
Why?
|
| STAT5 Transcription Factor | 1 | 2015 | 14 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 21 | 0.120 |
Why?
|
| Collagen | 1 | 2016 | 135 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2017 | 321 | 0.110 |
Why?
|
| Phenotype | 2 | 2016 | 1236 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2017 | 436 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 446 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2023 | 1561 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 198 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 899 | 0.100 |
Why?
|
| Female | 8 | 2026 | 34424 | 0.100 |
Why?
|
| Gene Expression | 1 | 2016 | 856 | 0.100 |
Why?
|
| Stilbenes | 1 | 2012 | 22 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 44 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 89 | 0.090 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Male | 8 | 2026 | 31410 | 0.090 |
Why?
|
| Disease Progression | 3 | 2026 | 1229 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2024 | 287 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1635 | 0.090 |
Why?
|
| Caspases | 1 | 2012 | 176 | 0.090 |
Why?
|
| Curcumin | 1 | 2011 | 82 | 0.080 |
Why?
|
| Autophagy | 1 | 2012 | 240 | 0.080 |
Why?
|
| Cadherins | 2 | 2021 | 90 | 0.080 |
Why?
|
| Dendritic Cells | 2 | 2026 | 534 | 0.070 |
Why?
|
| Cell Movement | 2 | 2021 | 484 | 0.060 |
Why?
|
| Regeneration | 2 | 2018 | 127 | 0.060 |
Why?
|
| Mutation | 3 | 2021 | 2674 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2016 | 39 | 0.060 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2025 | 9 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2025 | 12 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2025 | 22 | 0.060 |
Why?
|
| Snail Family Transcription Factors | 1 | 2025 | 29 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2026 | 220 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 30 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2025 | 109 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 588 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 22 | 0.050 |
Why?
|
| F-Box Proteins | 1 | 2024 | 16 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 690 | 0.050 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 19 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2025 | 182 | 0.050 |
Why?
|
| Netrin Receptors | 1 | 2023 | 1 | 0.050 |
Why?
|
| Methylation | 1 | 2024 | 130 | 0.050 |
Why?
|
| Netrin-1 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Retinoids | 1 | 2023 | 11 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 1292 | 0.050 |
Why?
|
| Albumin-Bound Paclitaxel | 1 | 2023 | 1 | 0.050 |
Why?
|
| Hepatic Stellate Cells | 1 | 2023 | 25 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2024 | 200 | 0.050 |
Why?
|
| Edema | 1 | 2023 | 42 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 46 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2194 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 102 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2024 | 198 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 859 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 755 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 134 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 218 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 57 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1012 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 132 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 34 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2019 | 45 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 875 | 0.040 |
Why?
|
| Oncogenes | 1 | 2018 | 70 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1030 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2018 | 218 | 0.030 |
Why?
|
| Palatine Tonsil | 1 | 2017 | 10 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 9 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 408 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2017 | 26 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2017 | 51 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2018 | 224 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 263 | 0.030 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2016 | 2 | 0.030 |
Why?
|
| L-Selectin | 1 | 2016 | 14 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2016 | 16 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2016 | 17 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 35 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2016 | 15 | 0.030 |
Why?
|
| Zinc Finger Protein Gli2 | 1 | 2016 | 26 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 617 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 48 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 196 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 203 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 18 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 15147 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2016 | 50 | 0.030 |
Why?
|
| Genes, ras | 1 | 2015 | 28 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2016 | 171 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 426 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2015 | 51 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 77 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2016 | 128 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 333 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 132 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 129 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 290 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 324 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 265 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1193 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 911 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2031 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 383 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 849 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3340 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 223 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 963 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2011 | 11 | 0.020 |
Why?
|
| Mitochondrial Membranes | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2011 | 29 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2011 | 24 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 50 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 48 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 737 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2011 | 109 | 0.020 |
Why?
|
| Lentivirus | 1 | 2011 | 64 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 233 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 108 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 206 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 391 | 0.020 |
Why?
|
| Cytosol | 1 | 2011 | 184 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 372 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 3779 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 993 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 18501 | 0.010 |
Why?
|